Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06549790 · ClinicalTrials.gov registry record · Phase 1
Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
A Phase 1 study of Relapsed/Refractory Acute Myeloid Leukemia, sponsored by Nerviano Medical Sciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 124
- Enrollment target
- 7
- Study locations
NCT06549790 is a Phase 1 study of Relapsed/Refractory Acute Myeloid Leukemia that is actively recruiting participants, run by Nerviano Medical Sciences. The registered enrollment target is 124 participants. The trial reports 7 study locations across 7 states.
The verdict
NCT06549790, a Phase 1 study of Relapsed/Refractory Acute Myeloid Leukemia, is actively recruiting participants, sponsored by Nerviano Medical Sciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 124 participants
- Enrollment target
- 7
- Study locations
Study Summary
The aim of PERKA-812-003 study is to investigate the safety, pharmacokinetics and preliminary anti-tumor activity of treatment with NMS-03597812 as single agent in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients who have exhausted standard treatment, including a subset of patients with TP53 mutations. It is anticipated that combination with venetoclax will be further evaluated following a future protocol amendment, once the Recommended Range Dose (RDR) as single agent has been defined.
Conditions Studied
Interventions
- DRUG NMS-03597812
Study Locations (7)
California
- City of Hope - Duarte - Duarte
Colorado
- Rocky Mountain Cancer Centers - Aurora
Delaware
- Medical Oncology Hematology Consultants - Newark
Georgia
- Blood and Marrow Transplant Group of Georgia - Atlanta
Minnesota
- Mayo Clinic Cancer Center (MCCC) - Rochester - Rochester
Ohio
- Gabrail Cancer Research Center - Canton
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2024-10-16 |
| Est. Completion | 2030-05-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06549790
The ClinicalTrials.gov registry entry for NCT06549790 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nerviano Medical Sciences, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed/Refractory Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which NMS-03597812 is the first listed.
NCT06549790 reports 7 study locations spanning 7 distinct geographic areas - top geographies include California, Colorado, Delaware.
Frequently Asked Questions
What is clinical trial NCT06549790 about?
NCT06549790 is a clinical study titled "Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia". The aim of PERKA-812-003 study is to investigate the safety, pharmacokinetics and preliminary anti-tumor activity of treatment with NMS-03597812 as single agent in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients who have exhausted standard treatment, including a subset of patients with...
What is the current status of trial NCT06549790?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 124 participants. The study started on 2024-10-16. Estimated completion is 2030-05-15.
What conditions does trial NCT06549790 study?
This clinical trial studies the following conditions: Relapsed/Refractory Acute Myeloid Leukemia.
What interventions are being tested in trial NCT06549790?
The interventions under investigation include: NMS-03597812 (DRUG).
Who is sponsoring clinical trial NCT06549790?
This trial is sponsored by Nerviano Medical Sciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06549790 being conducted?
This trial has 7 study locations across California, Colorado, Delaware, Georgia, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed/Refractory Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.